|
FR104E
(fr)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
EP0368684B2
(fr)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Clonage de séquences d'immunoglobulines de domaines variables.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1991016056A1
(fr)
|
1990-04-16 |
1991-10-31 |
The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce |
Emploi d'agonistes de recepteur purinergique utilises comme agents antineoplastiques
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5900407A
(en)
|
1997-02-06 |
1999-05-04 |
Inspire Pharmaceuticals, Inc. |
Method of treating dry eye disease with uridine triphosphates and related compounds
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
JP2003524636A
(ja)
|
1999-12-22 |
2003-08-19 |
インスパイアー ファーマシューティカルズ，インコーポレイティド |
プリン性受容体アゴニストによる胃腸管の処置方法
|
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート，エルエルシー |
Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
|
|
WO2002011763A1
(fr)
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Antagonistes de cd40 destines au traitement du psoriasis et d'autres inflammations cutanees
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
EP1322383B9
(fr)
|
2000-10-02 |
2006-09-06 |
Chiron Corporation |
Methodes therapeutiques pour lutter contre les cellules b malignes avec des anticorps antagonistes anti-cd40
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
WO2003075846A2
(fr)
|
2002-03-08 |
2003-09-18 |
Sloan-Kettering Institute For Cancer Research |
Utilisations d'anticorps 8h9 monoclonaux
|
|
EP1399187A4
(fr)
|
2000-10-18 |
2005-09-21 |
Sloan Kettering Inst Cancer |
Utilisations d'anticorps monoclonal 8h9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
KR20040020866A
(ko)
|
2000-12-14 |
2004-03-09 |
후지사와 야꾸힝 고교 가부시키가이샤 |
사일런스 항-ｃｄ28 항체 및 그의 용도
|
|
DK1345969T3
(da)
|
2000-12-26 |
2010-11-29 |
Inst Nat Sante Rech Med |
Anti-CD28-antistof
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
CA2658221C
(fr)
|
2001-04-27 |
2012-11-27 |
Kyowa Kirin Co., Ltd. |
Anticorps monoclonal anti-cd40
|
|
WO2003028712A2
(fr)
*
|
2001-09-28 |
2003-04-10 |
Universite Libre De Bruxelles |
Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
|
|
WO2003029296A1
(fr)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Anticorps humains diriges contre le cd40
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
|
AU2002346581A1
(en)
|
2001-11-26 |
2003-06-10 |
Chiron Corporation |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
EP2410332A1
(fr)
|
2002-11-21 |
2012-01-25 |
The University Of Utah |
Méthode d'identification de modulateurs purinergiques du système olfactif
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
US7618632B2
(en)
|
2003-05-23 |
2009-11-17 |
Wyeth |
Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
GB0324498D0
(en)
|
2003-07-21 |
2003-11-26 |
Aventis Pharma Inc |
Heterocyclic compounds as P2X7 ion channel blockers
|
|
EP1600164A3
(fr)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
US7923448B2
(en)
|
2003-11-03 |
2011-04-12 |
Cornell Research Foundation, Inc. |
Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
|
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
|
KR101128777B1
(ko)
|
2003-11-04 |
2012-04-13 |
조마 테크놀로지 리미티드 |
다발성 골수종을 치료하기 위한 길항제 항-ｃｄ４０단클론성 항체의 용도
|
|
WO2005044307A2
(fr)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Procedes de therapie pour des cancers lies a la cellule b
|
|
PL1680141T3
(pl)
|
2003-11-04 |
2011-04-29 |
Novartis Vaccines & Diagnostics Inc |
Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
SI1682177T1
(sl)
|
2003-11-04 |
2010-12-31 |
Novartis Vaccines & Diagnostic |
Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
CN1922316B
(zh)
|
2003-12-25 |
2011-03-23 |
协和发酵麒麟株式会社 |
抗cd40抗体突变体
|
|
CA2565211A1
(fr)
|
2004-04-29 |
2005-11-24 |
Abbott Laboratories |
Analogues d'amino-tetrazoles et methodes d'utilisation
|
|
US20050261239A1
(en)
*
|
2004-05-23 |
2005-11-24 |
Universiteit Van Maastricht |
Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
WO2006003179A2
(fr)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Anticorps anti-kir humains
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
SI1835937T1
(sl)
|
2005-01-06 |
2012-08-31 |
Novo Nordisk As |
Sestavki in postopki za zdravljenje virusne infekcije
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8323645B2
(en)
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
AU2006239318A1
(en)
|
2005-04-27 |
2006-11-02 |
Cs-Keys, Inc |
Cancer specific PCNA isoform binding antibodies and uses thereof
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
JP5421590B2
(ja)
|
2005-05-18 |
2014-02-19 |
ノバルティス アーゲー |
自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
|
|
AU2006247067B2
(en)
|
2005-05-18 |
2012-06-07 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
US8303955B2
(en)
|
2005-05-26 |
2012-11-06 |
Seattle Genetics, Inc. |
Humanized anti-CD40 antibodies and their methods of use
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
ES2400660T3
(es)
|
2005-11-01 |
2013-04-11 |
Novartis Ag |
Usos de anticuerpos anti-CD40
|
|
WO2007053661A2
(fr)
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Utilisations d'anticorps anti-cd40
|
|
CA2627114A1
(fr)
|
2005-11-07 |
2007-05-18 |
Abbott Laboratories |
Antagonistes des recepteurs p2x7 et methodes d'utilisation
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
WO2007067991A2
(fr)
|
2005-12-08 |
2007-06-14 |
Medarex, Inc. |
Anticorps monoclonaux humains se fixant a l'o8e
|
|
US20090304687A1
(en)
|
2005-12-09 |
2009-12-10 |
Seattle Genetics , Inc. |
Methods of using cd40 binding agents
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
WO2007109201A2
(fr)
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
|
|
AR060487A1
(es)
|
2006-04-21 |
2008-06-18 |
Xoma Technology Ltd |
Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
|
|
EP1854810A1
(fr)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
JP2010505426A
(ja)
|
2006-10-10 |
2010-02-25 |
バイオスセプター インターナショナル リミテッド |
非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
EP2097447A4
(fr)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
Anticorps monoclonaux humains contre le btla et procedes d'utilisation
|
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
|
EP2125893A2
(fr)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Anticorps cd40 optimisés et leurs procédés d'utilisation
|
|
CA2680761A1
(fr)
|
2007-03-22 |
2008-09-25 |
Astrazeneca Ab |
Derives de quinoleine destines au traitement de maladies inflammatoires
|
|
US20100143245A1
(en)
|
2007-03-22 |
2010-06-10 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
MX2009010759A
(es)
|
2007-04-03 |
2009-10-28 |
Glaxo Group Ltd |
Derivados de carboxamida imidazolidina como modulares de p2x7.
|
|
WO2008124153A1
(fr)
|
2007-04-10 |
2008-10-16 |
H. Lundbeck A/S |
Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
|
|
AU2008247382B2
(en)
|
2007-05-07 |
2014-06-05 |
Medimmune, Llc |
Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
US20110046137A1
(en)
|
2007-05-10 |
2011-02-24 |
Glaxo Group Limited |
Pyrazole Derivatives as P2X7 Modulators
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
JPWO2009001673A1
(ja)
*
|
2007-06-26 |
2010-08-26 |
学校法人 城西大学 |
Ａｔｐ含有免疫アジュバント
|
|
WO2009014708A2
(fr)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Anticorps pd-1 en combinaison avec une cellule sécrétant de la cytokine et leurs procédés d'utilisation
|
|
FR2921342B1
(fr)
|
2007-09-20 |
2010-03-12 |
Airbus France |
Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
|
|
WO2009053459A1
(fr)
|
2007-10-26 |
2009-04-30 |
Glaxo Group Limited |
Dérivés de 4-benzoyl-1-substitué-pipérazin-2-one comme modulateurs de p2x7
|
|
WO2009057827A1
(fr)
|
2007-10-31 |
2009-05-07 |
Nissan Chemical Industries, Ltd. |
Dérivés de pyridazinone et leur utilisation comme inhibiteurs du récepteur p2x7
|
|
MX2010005099A
(es)
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
|
PE20091036A1
(es)
|
2007-11-30 |
2009-08-15 |
Astrazeneca Ab |
Derivado de quinolina como antagonista del receptor p2x7
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
WO2009073809A2
(fr)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Conjugués glucidiques utilisés en tant qu'agents d'administration pour des oligonucléotides
|
|
CA2712989C
(fr)
|
2008-01-23 |
2015-10-27 |
Xencor, Inc. |
Anticorps diriges contre cd40 optimises et leurs procedes d'utilisation
|
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
|
KR101598397B1
(ko)
|
2008-04-22 |
2016-02-29 |
얀센 파마슈티카 엔.브이. |
퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
|
|
EP2279003A4
(fr)
|
2008-05-01 |
2013-04-03 |
Gtc Biotherapeutics Inc |
Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
|
|
CA2729567C
(fr)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps anti-cd27
|
|
ES2685823T3
(es)
|
2008-07-16 |
2018-10-11 |
Baylor Research Institute |
Anticuerpos antagonistas anti-CD40
|
|
PE20110385A1
(es)
|
2008-07-18 |
2011-06-22 |
Bristol Myers Squibb Co |
Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
AR073459A1
(es)
|
2008-07-18 |
2010-11-10 |
Domantis Ltd |
Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
WO2010042433A1
(fr)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
|
|
EP2367553B1
(fr)
|
2008-12-05 |
2017-05-03 |
Novo Nordisk A/S |
Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
|
|
EP3255060A1
(fr)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
|
|
EP2198873A1
(fr)
|
2008-12-18 |
2010-06-23 |
Aposcience AG |
Préparation pharmaceutique renfermant le surnageant de cultures de cellules mononucléaires sanguines
|
|
NZ594315A
(en)
|
2009-02-17 |
2013-05-31 |
Ucb Pharma Sa |
Antibody molecules having specificity for human ox40
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
AU2010222942B2
(en)
|
2009-03-10 |
2013-01-10 |
Baylor Research Institute |
Anti-CD40 antibodies and uses thereof
|
|
CN102770457A
(zh)
|
2009-03-10 |
2012-11-07 |
贝勒研究院 |
靶向抗原呈递细胞的疫苗
|
|
GB0906274D0
(en)
|
2009-04-09 |
2009-05-20 |
Ge Healthcare Ltd |
Imaging the central nervous system
|
|
JP5748653B2
(ja)
|
2009-04-10 |
2015-07-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
|
|
ES2829423T3
(es)
|
2009-04-20 |
2021-05-31 |
Kyowa Kirin Co Ltd |
Anticuerpo anti-CD40 que contiene IgG2 que presenta tres mutaciones de aminoácido introducidas en el mismo
|
|
JP5654001B2
(ja)
|
2009-04-29 |
2015-01-14 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
|
|
GB0907515D0
(en)
|
2009-04-30 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|
|
WO2010132389A2
(fr)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
|
|
ES2352780B2
(es)
*
|
2009-06-04 |
2011-09-15 |
Laboratorios Ovejero S.A. |
Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
|
|
WO2011012592A1
(fr)
|
2009-07-30 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Amides de dihydropyrimidone utilisés comme modulateurs p2x7
|
|
BR112012007875A2
(pt)
|
2009-07-31 |
2016-11-22 |
Medarex Inc |
anticorpos totalmente humanos para btla
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
WO2011031063A2
(fr)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
|
|
US8871760B2
(en)
|
2009-09-21 |
2014-10-28 |
Roche Palo Alto Llc |
[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
|
|
GB0919594D0
(en)
|
2009-11-09 |
2009-12-23 |
Glaxo Group Ltd |
Compounds
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
SG181533A1
(en)
|
2009-12-07 |
2012-07-30 |
Univ Leland Stanford Junior |
Methods for enhancing anti-tumor antibody therapy
|
|
KR101773216B1
(ko)
|
2009-12-29 |
2017-08-31 |
교와 핫꼬 기린 가부시키가이샤 |
항 ｃｄ27 항체
|
|
WO2011091078A2
(fr)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Variants d'anticorps possédant une activité complémentaire accrue
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
LT2536764T
(lt)
|
2010-02-18 |
2018-10-25 |
Ose Immunotherapeutics |
Anti-cd28 humanizuoti antikūnai
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
EP2542256B1
(fr)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
EP2560994B1
(fr)
|
2010-04-08 |
2016-10-12 |
JN Biosciences LLC |
Anticorps anti-cd122
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
JP5513242B2
(ja)
|
2010-04-28 |
2014-06-04 |
オリンパス株式会社 |
撮像装置
|
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
CA2809089C
(fr)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procedes d'utilisation
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
CA2812046A1
(fr)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Agents a base d'arni modifies
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EP2643350A4
(fr)
|
2010-11-22 |
2015-01-07 |
Innate Pharma Sa |
Traitements modulant les cellules tueuses naturelles et méthodes de traitement d'hémopathies malignes
|
|
WO2012075111A1
(fr)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
|
|
US20120149718A1
(en)
|
2010-12-14 |
2012-06-14 |
Brotherton-Pleiss Christine E |
Amido Compounds
|
|
US20120157494A1
(en)
|
2010-12-16 |
2012-06-21 |
Harris Iii Ralph New |
Isoindolyl compounds
|
|
WO2012087928A2
(fr)
|
2010-12-20 |
2012-06-28 |
The Rockefeller University |
Modulation d'anticorps agonistes anti-tnfr
|
|
WO2012109238A2
(fr)
|
2011-02-07 |
2012-08-16 |
President And Fellows Of Harvard College |
Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
US20140073651A1
(en)
|
2011-02-22 |
2014-03-13 |
Actelion Pharmaceuticals Ltd. |
Benzamide derivatives as p2x7 receptor antagonists
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
EP3147297B1
(fr)
|
2011-03-31 |
2018-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticorps dirigés contre l'icos et leurs utilisations
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
HUE038848T2
(hu)
|
2011-04-21 |
2018-11-28 |
Bristol Myers Squibb Co |
CD40-antagonista antitest polipeptidek
|
|
WO2012147713A1
(fr)
|
2011-04-25 |
2012-11-01 |
第一三共株式会社 |
Anticorps anti-b7-h3
|
|
WO2012149285A1
(fr)
|
2011-04-28 |
2012-11-01 |
Claire Mitchell |
Méthode de traitement d'une dégénérescence maculaire par la modulation des récepteurs p2y12 ou p2x7
|
|
ES2709654T3
(es)
|
2011-04-29 |
2019-04-17 |
Apexigen Inc |
Anticuerpos anti-CD40 y métodos de uso
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
|
MX349321B
(es)
|
2011-07-01 |
2017-07-21 |
Biosceptre (Aust) Pty Ltd |
Terapia combinada.
|
|
WO2013008171A1
(fr)
|
2011-07-11 |
2013-01-17 |
Glenmark Pharmaceuticals S.A. |
Anticorps qui se lient à l'ox40 et leurs utilisations
|
|
CN103687860B
(zh)
|
2011-07-22 |
2016-06-08 |
埃科特莱茵药品有限公司 |
作为p2x7受体拮抗剂的杂环酰胺衍生物
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
CA2845810C
(fr)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procedes d'utilisation
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
EP2604265A1
(fr)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
|
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
|
EP2858722B8
(fr)
|
2012-06-08 |
2018-02-21 |
Aduro BioTech, Inc. |
Compositions et procédés pour immunothérapie anticancéreuse
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
TWI598325B
(zh)
|
2012-10-12 |
2017-09-11 |
Ｈ 朗德貝克公司 |
苯甲醯胺類
|
|
TW201427947A
(zh)
|
2012-10-12 |
2014-07-16 |
Lundbeck & Co As H |
環狀胺
|
|
WO2014061277A1
(fr)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
|
|
EP2912063A1
(fr)
|
2012-10-23 |
2015-09-02 |
Bristol-Myers Squibb Company |
Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
|
|
JPWO2014065402A1
(ja)
|
2012-10-26 |
2016-09-08 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
KR102270618B1
(ko)
|
2012-10-30 |
2021-06-30 |
아펙시젠, 인코포레이티드 |
항-cd40 항체 및 사용 방법
|
|
US20150297623A1
(en)
*
|
2012-11-06 |
2015-10-22 |
The Board Of Regents Of The University Of Texas System |
Methods for treatment of primary cancer and cancer metastasis
|
|
US9695212B2
(en)
*
|
2012-12-13 |
2017-07-04 |
Aduro Biotech, Inc. |
Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
|
|
KR102232744B1
(ko)
|
2012-12-18 |
2021-03-26 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
|
|
EP2934598B1
(fr)
*
|
2012-12-19 |
2018-04-18 |
Board Of Regents, The University Of Texas System |
Ciblage pharmaceutique d'une voie de signalisation de dinucléotide cyclique chez un mammifère
|
|
CA2894879A1
(fr)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
Anticorps specifiques de b7-h4 et compositions et procedes pour les utiliser
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CA2896790C
(fr)
|
2013-01-22 |
2022-05-10 |
Actelion Pharmaceuticals Ltd |
Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
|
|
JO3509B1
(ar)
|
2013-03-14 |
2020-07-05 |
Janssen Pharmaceutica Nv |
معدلات p2x7
|
|
TWI644671B
(zh)
|
2013-03-14 |
2018-12-21 |
比利時商健生藥品公司 |
Ｐ２ｘ７調節劑
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US9604982B2
(en)
|
2013-03-14 |
2017-03-28 |
Janssen Pharmaceutica Nv |
P2X7 modulators
|
|
US9040534B2
(en)
|
2013-03-14 |
2015-05-26 |
Janssen Pharmaceutica Nv |
[1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
WO2014140374A2
(fr)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Anticorps monovalents anti-cd27
|
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
PE20160080A1
(es)
|
2013-05-18 |
2016-02-21 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
|
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
|
WO2014194302A2
(fr)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Protéines de liaison à l'antigène qui se lient à pd-1
|
|
SG11201509982UA
(fr)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
WO2014209168A1
(fr)
|
2013-06-24 |
2014-12-31 |
Kim Ruslan Zynsonovich |
Communicateur automobile
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
AU2014296887A1
(en)
|
2013-08-02 |
2016-01-28 |
Aduro Biotech Holdings, Europe B.V. |
Combining CD27 agonists and immune checkpoint inhibition for immune stimulation
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
CA2927009C
(fr)
*
|
2013-10-21 |
2019-04-23 |
Drexel University |
Utilisation d'agonistes de sting pour traiter une infection chronique par le virus de l'hepatite b
|
|
ES2707057T3
(es)
|
2013-11-06 |
2019-04-02 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
CN105611944A
(zh)
|
2013-12-20 |
2016-05-25 |
豪夫迈·罗氏有限公司 |
抗ang2抗体和cd40激动剂的组合疗法
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
EP2905282A1
(fr)
|
2014-02-05 |
2015-08-12 |
AXXAM S.p.A. |
Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
|
|
EP3113796A1
(fr)
|
2014-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
|
|
CN106413751A
(zh)
|
2014-05-21 |
2017-02-15 |
辉瑞大药厂 |
用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
|
|
SI3148579T1
(sl)
|
2014-05-28 |
2021-07-30 |
Agenus Inc. |
Proti GITR antitelesa in postopki z njihovo uporabo
|
|
EP3149040A1
(fr)
|
2014-05-29 |
2017-04-05 |
Spring Bioscience Corporation |
Anticorps anti-b7-h3 et leurs utilisations diagnostiques
|
|
WO2015188047A1
(fr)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
EP3157563A1
(fr)
|
2014-06-23 |
2017-04-26 |
TheraMAB LLC |
Compositions et méthodes pour une immunothérapie efficace et sûre
|
|
CN106659852A
(zh)
|
2014-07-09 |
2017-05-10 |
诺和诺德股份有限公司 |
机动化药物输送装置
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
CA2957146A1
(fr)
|
2014-08-12 |
2016-02-18 |
Alligator Bioscience Ab |
Polytherapies utilisant des anticorps anti-cd40
|
|
WO2016023875A1
(fr)
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Polythérapie d'anticorps activant le cd-40 humain et d'anticorps anti-pd-l1 humain
|
|
WO2016028810A1
(fr)
|
2014-08-18 |
2016-02-25 |
Biogen Ma Inc. |
Anticorps anti-cd40 et leurs utilisations
|
|
EP3183269A2
(fr)
|
2014-08-22 |
2017-06-28 |
Bristol-Myers Squibb Company |
Traitement du cancer à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un anticorps anti-cd137
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
DK3186283T3
(da)
|
2014-08-29 |
2020-03-02 |
Hoffmann La Roche |
Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1
|
|
WO2016040724A1
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anticorps anti-b7-h4 et immunoconjugués
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
KR20170075778A
(ko)
|
2014-10-27 |
2017-07-03 |
에이전시 포 사이언스, 테크놀로지 앤드 리서치 |
항-tim-3 항체
|
|
US11639384B2
(en)
|
2014-10-28 |
2023-05-02 |
University Children's Hospital Tübingen |
Treatment of pediatric BCP-ALL patients with an anti-KIR antibody
|
|
BR112017008959A2
(pt)
|
2014-10-29 |
2018-01-16 |
Seattle Genetics, Inc. |
método para tratamento de uma doença.
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
SI3215532T1
(sl)
|
2014-11-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Protitelesa proti TIM3 in postopki uporabe
|
|
JP6800853B2
(ja)
|
2014-12-11 |
2020-12-16 |
ピエール、ファーブル、メディカマン |
抗ｃ１０ｏｒｆ５４抗体およびその使用
|
|
EP3546473B1
(fr)
|
2014-12-16 |
2025-12-10 |
Kayla Therapeutics |
Dinucléotides cycliques [(2',5')p(3',5')p] fluorés pour l'induction de la cytokine
|
|
WO2016096577A1
(fr)
|
2014-12-16 |
2016-06-23 |
Invivogen |
Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer
|
|
US9963509B2
(en)
|
2014-12-23 |
2018-05-08 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
WO2016111947A2
(fr)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Anticorps inhibiteurs d'interactions de tim-3:lilrb2 et leurs utilisations
|
|
EA035817B1
(ru)
|
2015-03-10 |
2020-08-14 |
Адуро Байотек, Инк. |
Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
|
|
US20180125876A1
(en)
*
|
2015-05-20 |
2018-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
|
|
KR102222186B1
(ko)
|
2015-08-13 |
2021-03-03 |
머크 샤프 앤드 돔 코포레이션 |
Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
|
|
JP2018534295A
(ja)
|
2015-10-28 |
2018-11-22 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
|
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
US20190062272A1
(en)
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
EP3507367A4
(fr)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
PT3523287T
(pt)
|
2016-10-04 |
2021-10-06 |
Merck Sharp & Dohme |
Compostos de benzo[b]tiofeno como agonistas de sting
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
PE20210255A1
(es)
|
2016-12-01 |
2021-02-10 |
Takeda Pharmaceuticals Co |
Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
|
|
WO2018118665A1
(fr)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Agonistes dinucléotidiques cycliques de sting pour le traitement du cancer
|
|
AU2017378782A1
(en)
|
2016-12-20 |
2019-07-04 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
CN110234403A
(zh)
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
US11021511B2
(en)
|
2017-01-27 |
2021-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
UA125730C2
(uk)
|
2017-06-22 |
2022-05-25 |
Курадев Фарма Лімітед |
Низькомолекулярні модулятори sting людини
|
|
WO2018234807A1
(fr)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
Modulateurs hétérocycliques à petites molécules de sting humain
|
|
US20200138827A1
(en)
|
2017-06-22 |
2020-05-07 |
Curadev Pharma Limited |
Small molecule modulators of human sting
|
|
RU2020109328A
(ru)
|
2017-08-04 |
2021-09-06 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака
|
|
JP2020530838A
(ja)
|
2017-08-04 |
2020-10-29 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
|
|
CN107335049B
(zh)
*
|
2017-08-18 |
2019-10-18 |
中国药科大学 |
菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用
|
|
WO2019046511A1
(fr)
|
2017-08-31 |
2019-03-07 |
Sperovie Biosciences, Inc. |
Composés, compositions et méthodes pour le traitement d'une maladie
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
SG11202002218VA
(en)
|
2017-09-15 |
2020-04-29 |
Aduro Biotech Inc |
Pyrazolopyrimidinone compounds and uses thereof
|
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
|
EP3691640A1
(fr)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Méthodes d'administration d'agonistes de sting
|